Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Intervacc AB

Market Cap 443M 46.36M 40.4M 37.24M 35.03M 65.53M 4.37B 65.99M 172M 2.15B 174M 170M 7.46B P/E 2026 *
-5.42x
P/E 2027 * -5.42x
Enterprise Value 356M 37.26M 32.47M 29.93M 28.15M 52.66M 3.51B 53.03M 138M 1.73B 140M 137M 6B EV / Sales 2026 *
22.3x
EV / Sales 2027 * 11.6x
Free-Float
80.66%
Yield 2026 *
-
Yield 2027 * -
1 day-0.76%
1 week-2.99%
Current month+4.84%
1 month+8.51%
3 months+79.31%
6 months+46.73%
Current year+40.69%
1 week 1.29
Extreme 1.292
1.38
1 month 1.15
Extreme 1.15
1.38
Current year 0.57
Extreme 0.572
1.46
1 year 0.57
Extreme 0.572
1.46
3 years 0.57
Extreme 0.572
10.46
5 years 0.57
Extreme 0.572
89.3
10 years 0.57
Extreme 0.572
95.5
Manager TitleAgeSince
Chief Executive Officer 70 2026-02-04
Director of Finance/CFO - 2020-02-05
Chief Tech/Sci/R&D Officer - 2020-06-10
Director TitleAgeSince
Chairman 56 2026-05-12
Director/Board Member 72 2023-12-31
Director/Board Member 68 2024-12-31
Date Insider Type Main position Quantity % Market Cap.
25-02-22Free

Chief Financial Officer

929,208 1.2269%
25-02-16Sell

Chief Executive Officer

278,820 0.3681%
25-02-16Buy

Chief Executive Officer

135,000 0.1783%
Change 5-day change 1-year change 3-year change Capi.($)
-0.76%-2.99%+36.41%-83.23% 46.36M
+0.84%-1.84%+62.55%+113.61% 54.44B
+4.60%+5.82%+56.35%+43.04% 45.8B
-1.44%+1.51%-12.94%-19.24% 22.98B
-2.69%-0.95%-3.68%+379.00% 20.76B
+3.22%+2.94%+24.02%-35.05% 16.25B
+0.86%+1.48%+17.19%-37.81% 15.34B
-1.01%-2.97%+27.42%+171.92% 13.05B
+3.07%+5.43%+21.37% - 12.37B
+4.95%+13.49%+121.11%+249.05% 12.47B
Average +1.17%+1.67%+34.98%+86.81% 21.35B
Weighted average by Cap. +1.50%+1.38%+39.34%+98.33%

Financials

2026 *2027 *
Net sales 16M 1.67M 1.46M 1.34M 1.26M 2.37M 158M 2.38M 6.21M 77.77M 6.28M 6.15M 270M 30M 3.14M 2.74M 2.52M 2.37M 4.44M 296M 4.47M 11.65M 146M 11.78M 11.53M 505M
Net income -81.6M -8.54M -7.44M -6.86M -6.45M -12.07M -805M -12.15M -31.69M -397M -32.05M -31.37M -1.37B -83.3M -8.72M -7.6M -7M -6.59M -12.32M -822M -12.41M -32.35M -405M -32.72M -32.02M -1.4B
Net Debt -87M -9.1M -7.93M -7.31M -6.88M -12.87M -858M -12.96M -33.79M -423M -34.17M -33.44M -1.47B -96M -10.05M -8.75M -8.07M -7.59M -14.2M -947M -14.3M -37.28M -467M -37.71M -36.9M -1.62B
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
16
Date Price Change Volume
26-06-18 1.300 kr -0.76% 538,301
26-06-17 1.310 kr -2.24% 375,168
26-06-16 1.340 kr +1.52% 404,662
26-06-15 1.320 kr -2.22% 364,136
26-06-12 1.350 kr +0.75% 795,219

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IVACC Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!